Hepatocellular carcinoma is a leading cause of cancer-related death globally. The treatment of hepatocellular carcinoma is complex, with diverse therapeutic approaches and their combinations available ...

Use of pathological response versus RECIST assessment in predicting relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma. Expanded biomarker analysis of an ...

Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have increased year by year. HCC research has increasingly focused on ...

Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy. BMC Research Notes , 2024; 17 (1) DOI: 10.1186/s13104-024-07016-y Cite This Page : ...

A new study in the Journal of Interferon & Cytokine Research (JICR) showed that a specific retinoic acid-inducible gene I ...

Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

A newly developed nomogram predicts preoperative microvascular invasion in patients with HCC, improving surgical planning and outcomes.

On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...

Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have ...